A 39-year-old man with HIV began treatment for severe disseminated histoplasmosis 15 months ago. After 2 weeks of induction therapy with intravenous liposomal amphotericin B, he started maintenance therapy with oral itraconazole (200 mg three times a day for 3 days, then 200 mg twice daily). After 1 year, the itraconazole dose was reduced to 200 mg once daily as long-term suppressive therapy. He has received antiretroviral therapy for 14 months with persistently undetectable HIV RNA levels. After 6 months of antiretroviral therapy, the CD4 count increased from a nadir of 28 cells/mm3 to 225 cells/mm3. Recent laboratory studies show a CD4 count of 276 cells/mm3, negative fungal blood cultures, and negative serum Histoplasma antigen.
Which one of the following is the appropriate next step regarding antifungal therapy?
 Sign In or Register Progress Not Saved!
Since you are not signed in, your progress won't be saved.
	Since you are not signed in, your progress won't be saved.
Question Last Updated
January 29th, 2025
				
			January 29th, 2025
Steps to Acquire CE for this Question Bank Topic:
							1
						Answer
Answer all questions
							2
						Score 80%+
Answer correctly
							3
						Claim CE
Choose CNE or CME
							4
						Give Feedback
Complete survey
							5
					
Bictegravir-Tenofovir alafenamide-Emtricitabine Biktarvy
Darunavir-Cobicistat-Tenofovir alafenamide-Emtricitabine Symtuza
Dolutegravir-Abacavir-Lamivudine Triumeq
Dolutegravir-Lamivudine Dovato
Dolutegravir-Rilpivirine Juluca
Doravirine-Tenofovir DF-Lamivudine Delstrigo
Efavirenz-Tenofovir DF-Emtricitabine Atripla
Elvitegravir-Cobicistat-Tenofovir alafenamide-Emtricitabine Genvoya
Elvitegravir-Cobicistat-Tenofovir DF-Emtricitabine Stribild
Rilpivirine-Tenofovir alafenamide-Emtricitabine Odefsey
Rilpivirine-Tenofovir DF-Emtricitabine Complera
Fostemsavir Rukobia
Ibalizumab Trogarzo
Maraviroc Selzentry
Dolutegravir Tivicay
Raltegravir Isentress
Doravirine Pifeltro
Efavirenz Sustiva
Etravirine Intelence
Rilpivirine Edurant